February 27, 2023
Intercept Pharmaceuticals, MSN Pharmaceuticals and Apotex told a Delaware federal judge that they've cut deals to end Intercept's claims that Apotex's proposed generic version of Ocaliva, treatment for a rare liver disease, infringes its patents, resolving the consolidated litigation just as the parties were to face off in a bench trial on Monday.